- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04433975
Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes (Persist)
February 14, 2024 updated by: Mark A. Ilgen, University of Michigan
Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes: A Randomized Controlled Trial
The purpose of this research study is to look at the effect of programs aimed at helping people manage chronic pain and medication treatment.
The program sessions focus on educational information and strategies for pain and medication management.
The researchers enroll people who have chronic pain and have recently begun buprenorphine treatment to see if participants could benefit from these programs.
This research study will help the researchers learn how to improve current therapies for pain and medication management.
Study Overview
Status
Active, not recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mandy Lewis, MS
- Phone Number: 734-474-0702
- Email: mstinchc@med.umich.edu
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Michigan Medicine
-
Ann Arbor, Michigan, United States, 48105
- Veterans Affair Ann Arbor Healthcare System
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- having a diagnosis of an opioid use disorders (OUD) within the past 12 months;
- started buprenorphine (the term we use to refer to all buprenorphine products including buprenorphine/naloxone) treatment within the past 6 months
- at least moderate or greater self-reported pain on average over the past 3 months;
- regular and consistent access to a telephone and willingness to use the phone for study sessions.
Exclusion Criteria:
- buprenorphine medication prescribed in the form of a monthly injection and/or a transdermal patch
- self-reported pregnancy at the time of study enrollment
- currently living outside of the United States
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Psychosocial Pain Management (PPMI)
Eight Cognitive Behavioral Therapy-based individual telephone or video therapy sessions with research study therapist.
|
The main theme of the treatment is to provide participants with new ways of thinking and coping skills related to managing pain and opioid use in order to increase the likelihood the participant may remain in buprenorphine treatment.
|
Active Comparator: Enhanced Usual Care (EUC)
Two individual telephone educational sessions with research study therapist.
|
The EUC condition is designed to match the PPMI condition in terms of the non-specific aspects of receiving support for pain, substance use, and receiving monitoring of buprenorphine adherence.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retention on buprenorphine treatment according to TimeLine Follow-Back
Time Frame: Up to 3-months post enrollment
|
Retention on buprenorphine treatment will be operationalized as time to first episode of buprenorphine treatment non-adherence.
Non-adherence, or discontinuation of treatment, will be defined as a consecutive period of 7 or more calendar days without taking buprenorphine.
Buprenorphine retention data will be collected as part of the TimeLine Follow-Back (TLFB) assessment, which will be administered at the baseline enrollment assessment and the 1- and 3-month follow-ups in which the participant will be asked to recall on which days they took their buprenorphine medications.
|
Up to 3-months post enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retention on buprenorphine treatment according to TimeLine Follow-Back
Time Frame: Up to 12-months post enrollment
|
Retention on buprenorphine treatment will be operationalized as time to first episode of buprenorphine treatment non-adherence.
Non-adherence, or discontinuation of treatment, will be defined as a consecutive period of 7 or more calendar days without taking buprenorphine.
Buprenorphine retention data will be collected as part of the TimeLine Follow-Back (TLFB) assessment, which will be administered at the baseline enrollment assessment and the 1-, 3-, 6-, 9-, and 12-month follow-ups in which the participant will be asked to recall on which days they took their buprenorphine medications.
|
Up to 12-months post enrollment
|
Change from baseline in self-reported level of pain intensity on the Numerical Rating Scale for Pain Intensity (NRS-I).
Time Frame: Up to 3-months post enrollment
|
Pain level will be measured using the Numerical Rating Scale for Pain Intensity (NRS-I), an 11-point numeric rating scale (0 = no pain, 10 = worst pain imaginable), which will be collected at the baseline enrollment assessment and the 1- and 3--month follow-ups.
For each follow-up time point, we will subtract the baseline value to obtain a change score.
|
Up to 3-months post enrollment
|
Change from baseline in self-reported level of pain related functioning on the Brief Pain Inventory - Short Form (BPI)
Time Frame: Up to 3-months post enrollment
|
Pain-related functioning will be measured using the pain interference subscale of the Brief Pain Inventory - Short Form (BPI).
For this study, an increase in pain-related functioning will be operationalized as a reduction in the pain interference scale scores over time.
The BPI interference subscale measures how much pain has interfered with seven daily activities and will provide a current level of pain-related functioning (past 24-hours) at each follow-up (1- and 3-months).
BPI pain interference will be calculated as the mean of the seven interference items.
For each follow-up time point, we will subtract the baseline value to obtain a change score.
|
Up to 3-months post enrollment
|
Change from baseline in self-reported level of pain related functioning on the Pain Interference measure
Time Frame: Up to 3-months post enrollment
|
Pain-related functioning will be measured using the Pain Interference measure, which encompasses questions from Patient-Reported Outcomes Measurement Information System (PROMIS) Health Systems item bank v1.1.
For this study, an increase in pain-related functioning will be operationalized as a reduction in the pain interference scale scores over time.
The PROMIS Pain Interference item banks assess pain functioning over the past 7 days at each follow-up (1- and 3-months) and assesses consequences of pain on variables including the extent to which pain interferes with social, cognitive, emotional, physical, and recreational activities.
This measure will be scored using an Item Response Theory (IRT) scoring metric.
For each follow-up time point, we will subtract the baseline value to obtain a change score.
|
Up to 3-months post enrollment
|
Percent days abstinent from substance use on the TimeLine Follow-Back
Time Frame: Up to 3-months post enrollment
|
Frequency of substance use will be measured using the TimeLine Follow-Back and will be collected at the baseline assessment and the 1- and 3-month follow-ups.
During the administration, the participant will be asked to recall their alcohol and drug use utilizing a calendar-assisted structured interview that provides the participant with temporal cues to increase the accuracy of recall.
At the baseline assessment, retrospective data will be collected for the 6-months prior to study enrollment.
At each follow-up, data will be collected for the entire period since the previous date of data collection.
Percent days abstinent from substances (e.g.
alcohol and drugs) will be used as the primary measure of substance use.
|
Up to 3-months post enrollment
|
Change from baseline in self-reported level of pain intensity on the Numerical Rating Scale for Pain Intensity (NRS-I).
Time Frame: Up to 12-months post enrollment
|
Pain level will be measured using the Numerical Rating Scale for Pain Intensity (NRS-I), an 11-point numeric rating scale (0 = no pain, 10 = worst pain imaginable), which will be collected at the baseline enrollment assessment and the 1-, 3-, 6-, 9-, and 12-month follow-ups.
For each follow-up time point, we will subtract the baseline value to obtain a change score.
|
Up to 12-months post enrollment
|
Change from baseline in self-reported level of pain related functioning on the Brief Pain Inventory - Short Form (BPI)
Time Frame: Up to 12-months post enrollment
|
Pain-related functioning will be measured using the pain interference subscale of the Brief Pain Inventory - Short Form (BPI).
For this study, an increase in pain-related functioning will be operationalized as a reduction in the pain interference scale scores over time.
The BPI interference subscale measures how much pain has interfered with seven daily activities and will provide a current level of pain-related functioning (past 24-hours) at each follow-up (1-, 3-, 6-, 9-, and 12-months).
BPI pain interference will be calculated as the mean of the seven interference items.
For each follow-up time point, we will subtract the baseline value to obtain a change score.
|
Up to 12-months post enrollment
|
Change from baseline in self-reported level of pain related functioning on the Pain Interference measure
Time Frame: Up to 12-months post enrollment
|
Pain-related functioning will be measured using the Pain Interference measure, which encompasses questions from Patient-Reported Outcomes Measurement Information System (PROMIS) Health Systems item bank v1.1.
For this study, an increase in pain-related functioning will be operationalized as a reduction in the pain interference scale scores over time.
The PROMIS Pain Interference item banks assess pain functioning over the past 7 days at each follow-up (1-, 3-, 6-, 9-, and 12-months) and assesses consequences of pain on variables including the extent to which pain interferes with social, cognitive, emotional, physical, and recreational activities.
This measure will be scored using an Item Response Theory (IRT) scoring metric.
For each follow-up time point, we will subtract the baseline value to obtain a change score.
|
Up to 12-months post enrollment
|
Percent days abstinent from substance use on the TimeLine Follow-Back
Time Frame: Up to 12-months post enrollment
|
Frequency of substance use will be measured using the TimeLine Follow-Back and will be collected at the baseline assessment and the 1-, 3-, 6-, 9-, and 12-month follow-ups.
During the administration, the participant will be asked to recall their alcohol and drug use utilizing a calendar-assisted structured interview that provides the participant with temporal cues to increase the accuracy of recall.
At the baseline assessment, retrospective data will be collected for the 6-months prior to study enrollment.
At each follow-up, data will be collected for the entire period since the previous date of data collection.
Percent days abstinent from substances (e.g.
alcohol and drugs) will be used as the primary measure of substance use.
|
Up to 12-months post enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Allison Lin, M.D., M.S., University of Michigan
- Principal Investigator: Mark Ilgen, Ph.D., University of Michigan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 14, 2020
Primary Completion (Estimated)
August 31, 2024
Study Completion (Estimated)
August 31, 2024
Study Registration Dates
First Submitted
June 12, 2020
First Submitted That Met QC Criteria
June 12, 2020
First Posted (Actual)
June 16, 2020
Study Record Updates
Last Update Posted (Estimated)
February 15, 2024
Last Update Submitted That Met QC Criteria
February 14, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00166747
- R33AT010106 (U.S. NIH Grant/Contract)
- R01AT010797 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pain
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE) and other collaboratorsCompletedChronic Pain | Chronic Pain Syndrome | Chronic Pain, Widespread | Chronic Pain Due to Trauma | Chronic Pain Due to Malignancy (Finding) | Chronic Pain Due to Injury | Chronic Pain Post-Procedural | Chronic Pain HipUnited Kingdom
-
Consorci Sanitari de l'Alt Penedès i GarrafRecruitingChronic Post Operative Pain | Chronic Post-surgical Pain | Chronic Knee PainSpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
University of Alabama, TuscaloosaPatient-Centered Outcomes Research Institute; East Carolina University; Whatley...CompletedPain | Chronic Pain | Chronic Pain Syndrome | Widespread Chronic Pain | Chronic Pain Due to InjuryUnited States
-
University of UtahRecruitingChronic Pain | Chronic Pain Syndrome | Widespread Chronic PainUnited States
-
Evolve Restorative CenterFlowonix Medical; Celéri Health, Inc.; Advanced Infusion SolutionsCompletedPain, Chronic | Pain, Intractable | Chronic Nonmalignant PainUnited States
-
Assiut UniversityNot yet recruiting
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Thoracotomy | Postoperative Pain, Acute | Postoperative Pain, ChronicTurkey
-
Istanbul UniversityCompletedLow Back Pain, Mechanical, Biofeedback, Pain, Chronic
-
Apurano Pharmaceuticals GmbHRecruitingPain | Lower Back Pain | Back Pain | Chronic Pain | Pain, Chronic | Chronic Pain Syndrome | Pain Syndrome | Lower Back Pain ChronicGermany
Clinical Trials on Psychosocial Pain Management (PPMI)
-
Indiana University Melvin and Bren Simon Cancer...National Cancer Institute (NCI)UnknownDepression | Pain | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedDepression | Fatigue | Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone... and other conditionsUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedDepression | Pain | Lymphoma | Myelodysplastic Syndromes | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Anxiety DisorderUnited States
-
Homewood Research InstituteSt. Joseph's Healthcare Hamilton; Canadian Institutes of Health Research (CIHR) and other collaboratorsRecruitingPost Traumatic Stress Disorder | Cognitive DeficitCanada
-
University of TorontoMount Sinai Hospital, New YorkCompleted
-
Wake Forest University Health SciencesCompletedStage I Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of TorontoUnity Health TorontoUnknown
-
Virginia Commonwealth UniversityCompletedPain | Neurotoxicity | Peripheral Neuropathy | Cancer-related Problem/ConditionUnited States
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedMultiple Sclerosis | Low Back Pain | Chronic Pain | Muscular Dystrophies | Spinal Cord Injury | Other and Unspecified Amputation Stump ComplicationsUnited States
-
Northwestern UniversityNational Institute of Mental Health (NIMH)CompletedBipolar Disorder | Bipolar I DisorderUnited States